Tranexamic acid inhibits mitochondrial DNA release and reduces inflammatory response in an in vitro model of OGD/R-induced Caco-2 cell injury Authors: Ziyue Wang, Liman Huo, Hong Liu, Shuwei Shi, Rui Feng Published: 2026 ABSTRACT BackgroundIschemia-reperfusion (I/R) injury of the intestine remains a challenging clinical issue, and there is currently no definitive treatment protocol. Tranexamic acid (TXA), an antifibrinolytic drug used in bleeding patients, has been shown in previous studies to protect the intestinal epithelial barrier, but the specific mechanism remains unclear. This study aimed to explore the molecular mechanisms by which TXA protects the intestinal barrier after intestinal I/R.MethodsThe cell viability assay was assessed to verify the cytotoxicity of TXA toward Caco-2 cells. A Caco-2 cell oxygen-glucose deprivation-reperfusion (OGD/R) model was established. The transepithelial electrical resistance (TEER) of Caco-2 cell monolayers and FITC-dextran permeability assays were performed to assess the intestinal barrier function. The JC-1 fluorescent probe was used for assessment of mitochondrial membrane potential. Quantitative PCR (qPCR) was used to quantify mitochondrial DNA (mtDNA) released by Caco-2 cells, and enzyme-linked immunosorbent assay (ELISA) was employed to assess inflammatory factors.ResultsTXA reversed OGD/R-induced decreases in TEER and increases in FITC-dextran permeability in Caco-2 cell monolayers. Microscopy images of the Caco-2 monolayer also support these results. Additionally, TXA enhanced mitochondrial membrane potential, suppressed mtDNA release and alleviated inflammatory responses.ConclusionsTXA protects the intestinal barrier after intestinal I/R by enhancing mitochondrial membrane potential, inhibiting mtDNA release and reducing inflammation, suggesting its potential as a therapeutic agent for intestinal I/R injury.Supplementary InformationThe online version contains supplementary material available at 10.1186/s40360-026-01160-w. Introduction The intestine, widely recognized as the tissue most vulnerable to ischemia-reperfusion (I/R) injury, primarily sustains such damage following acute mesenteric ischemia, hemorrhagic shock, trauma, sepsis, burns, or surgical procedures [1]. Ischemia causes tissue hypoxia, toxin accumulation, and energy depletion, triggering cell necrosis and mitochondrial dysfunction. Paradoxically, restoring blood flow induces excessive reactive oxygen species (ROS) and nitrogen species, exacerbating inflammation and cellular damage, which further worsens organ injury and promotes apoptosis [2]. Intestinal mucosal barrier dysfunction and increased permeability provides a conduit for numerous bacteria or toxins from the luminal environment to enter the circulatory system, leading to multiple organ dysfunction syndrome and systemic inflammatory response syndrome (SIRS) [3]. Mitochondrial DNA (mtDNA) which is double-stranded circular 16.5 kbp DNA with a low degree of methylation is vulnerable to accumulating oxidative stress because of its proximity to mitochondrial ROS and the lack of protective histones [4]. Fragments of mtDNA, known as damage-associated molecular patterns (DAMPs), are released into the cytosol or extracellular because of mitochondrial stress and damage, leading to systemic inflammation and organ dysfunction through TLR-9, NLRP3 inflammasome, and cGAS-STING signal pathway [5]. Accumulating evidence has demonstrated that mtDNA serves as a marker for intestinal I/R injury and plays an active and initiative role in furthering inflammation and cell death [6–7]. Tranexamic acid (TXA) is a popular antifibrinolytic drug widely used in hemorrhagic trauma patients and cardiovascular, orthopedic, and gynecological surgical patients [8]. The CRASH-2 study has demonstrated the life-saving effect of early TXA application in trauma patients [9]. In recent studies, Tranexamic acid has been shown to play a role in regulating gut homeostasis and barrier integrity [10–11]. However, it remains unclear how TXA affects intestinal I/R injury. It seems that the mechanisms of TXA may not be limited to the inhibition of plasmin maturation [12]. Understanding TXA’s cellular and molecular mechanisms is key to defining its therapeutic scope. A previous study demonstrated that TXA decreased the release of mtDNA from endothelial cells and neutrophils. Therefore, we hypothesized that TXA could protect the intestinal barrier following I/R by suppressing the release of mtDNA and reducing inflammatory response. To substantiate this hypothesis, we performed in vitro studies, allowing evaluation of TXA treatment while avoiding the complexity of SIRS in in vivo injury models. Caco-2 cells were induced by oxygen-glucose deprivation-reoxygenation (OGD/R) to establish intestinal I/R model [13]. Materials and methods Reagents and materials TXA injection (5mL:0.5 g) was purchased from Brilliant Pharmaceutical Co. Ltd. (Chengdu, China). Caco-2 cells (NO. ZQ 0056) were obtained from Shanghai Yizefeng Biotechnology Co. Ltd. (Shanghai, China). Viva Cell (Shanghai, China) offered fetal bovine serum (FBS), Roswell Park Memorial Institute (RPMI) 1640 medium and trypsin-EDTA solution. Report (Shijiazhuang, China) offered Hank’s balanced salt solution (HBSS), phosphate buffered saline (PBS) and 1% penicillin/streptomycin solution. Sigma-Aldrich (St. Louis, MO, USA) offered FITC-dextran (MW 4000). Zymo Research (Irvine, CA, USA) applied ZR Plasmid MiniPrep Kit (Zymo Cat. No. D4015). Zhongshi Tontru (Tianjin, China) offered SYBR-Green dye. The primers were provided by Genewiz (Suzhou, China). Abcam (Cambridge, UK) provided mitochondrial DNA isolation kit (ab65321). Abclonal (Wuhan, China) offered assay kits for double-antibody sandwich Enzyme-Linked Immunosorbent Assay (ELISA) of interleukin-1β (IL-1β) and interleukin-6 (IL-6). Abbkine (Wuhan, China) provided CCK-8 reagent (BMU106). Biyuntian (Shanghai, China) provided the JC-1 fluorescent probe (C2006S). Cell cultures Caco-2 cells were cultured with RPMI 1640 medium containing 10% FBS and 1% penicillin/streptomycin solution at 37°C in the atmosphere of 5% CO2. Cells at passages 5–15, at 90–100% confluency were utilized for TXA studies. Animal Two inbred male C57BL/6 mice (age, 5–6 weeks; weight, 18–20 g) were a gift from Animal Center of the Fourth Hospital of Hebei Medical University. The animal experiments and husbandry were carried out under the guidelines of the Animal Ethics Committee of the Fourth Hospital of Hebei Medical University (Approval Code: 20240014; Approval Date: April 10th, 2024). The mice used in this study were handled with strict adherence to the authorized guidelines. Mice were anesthetized with an intraperitoneal injection of sodium pentobarbital (40 mg/kg). After confirming deep anesthesia (loss of righting reflex), euthanasia was performed by cervical dislocation. Drug preparation For drug preparation, this study employed a clinically approved, standardized injectable formulation of TXA (100 mg/mL) as the stock solution. This formulation contains only water for injection as an excipient, with no organic solvents or other additives that could interfere with cellular function. Working concentrations were prepared by directly and precisely diluting the stock solution into pre-warmed, sterile Caco-2 cell culture medium using calibrated pipettes under strict aseptic conditions. It is important to note that the volume of water for injection introduced during dilution was minimal (≤ 0.1% of the total medium volume), which is well below the threshold known to affect cellular physiology. Cell viability assay The cytotoxicity of TXA on Caco-2 cells was evaluated using a CCK-8 assay in accordance with the manufacturer’s instructions. Caco-2 cells were seeded into 96-well plates at a density of 1 × 10⁵ cells per well and cultured for 24 h. Subsequently, cells were treated with TXA at final concentrations of 0, 6.3, 15, 24 and 50 µg/mL for 24 h. Thereafter, 10 µL of CCK-8 solution was added to each well, and the plates were further incubated for 2 h. The absorbance was then measured at a wavelength of 450 nm using a microplate reader (Thermo Fisher Scientific, Waltham, MA, USA). In vitro model of OGD/R-induced Caco-2 cell injury and grouping To establish the OGD/R-induced cell injury model, Caco-2 cells were first starved in serum-free medium for 12 h, then transferred to RPMI 1640 medium without glucose and placed in a hypoxic environment using AnaeroPack-Anaero (Mitsubishi Gas Chemical, Tokyo, Japan) for 6 h, Following this, the cells were reoxygenated under normoxic conditions with complete medium for 12 h. Cells were randomly divided into five groups in this study (Fig. 1): (1) Control group: cells were cultured in complete medium under normoxic conditions for 30 h; (2) TXA group: cells were cultured in complete medium under normoxic conditions for 18 h, then cultured in complete medium containing TXA (24 µg/mL) under normoxic conditions for 12 h; (3) OGD/R group: cells were starved in serum-free medium for 12 h, followed by transfer to a oxygen-glucose deprivation environment for 6 h, then reoxygenated under normoxic conditions for 12 h; (4) OGD/R + TXA (L) group and (5) OGD/R + TXA (H) group: cells were cultured under OGD/R group conditions, and TXA at low (6.3 µg/mL) and high (24 µg/mL) concentrations was subsequently added immediately at the start of reoxygenation. Fig. 1Experimental protocols in OGD/R-injured Caco-2 cells. Group 1 served as the control group, where cells were cultured in complete medium under normoxic conditions for 30 h; Group 2 was the TXA group, where cells were cultured in complete medium under normoxic conditions for 18 h, followed by incubation in complete medium supplemented with 24 µg/mL TXA under normoxic conditions for another 12 h. Group 3 was the OGD/R group, where cells were starved in serum-free medium for 12 h, subjected to oxygen-glucose deprivation for 6 h, and then reoxygenated under normoxic conditions for 12 h. Groups 4 and 5 were the OGD/R + TXA (L) and OGD/R + TXA (H) groups, respectively, where cells were treated as in the OGD/R group, with low (6.3 µg/mL) and high (24 µg/mL) concentrations of TXA added immediately at the onset of reoxygenation Experimental protocols in OGD/R-injured Caco-2 cells. Group 1 served as the control group, where cells were cultured in complete medium under normoxic conditions for 30 h; Group 2 was the TXA group, where cells were cultured in complete medium under normoxic conditions for 18 h, followed by incubation in complete medium supplemented with 24 µg/mL TXA under normoxic conditions for another 12 h. Group 3 was the OGD/R group, where cells were starved in serum-free medium for 12 h, subjected to oxygen-glucose deprivation for 6 h, and then reoxygenated under normoxic conditions for 12 h. Groups 4 and 5 were the OGD/R + TXA (L) and OGD/R + TXA (H) groups, respectively, where cells were treated as in the OGD/R group, with low (6.3 µg/mL) and high (24 µg/mL) concentrations of TXA added immediately at the onset of reoxygenation Transepithelial electrical resistance (TEER) measurements Caco-2 cells (5 × 105/mL) were seeded on the apical surface of Transwell chamber with 4.5 μm pores (polycarbonate membrane, Biofil, Guangzhou, China) and allowed to form polarized monolayers according to the Caco-2 cell protocol [14]. Cell monolayer integrity was assessed by measuring TEER with MILLICEL@-ERS-2 (Millipore, Burlington, MA, USA). Inserts without cells were used as blanks. TEER (Ω·cm2) = (Sample resistance value - blank control value) × Membrane surface area of Transwell chamber. Cell permeability assays The Caco-2 cells were inoculated into the upper chamber of Transwell and cultured for 21 days, then treated as described earlier. At the end of the experiment, medium was removed, and monolayers were washed twice with pre-warmed PBS. FITC-dextran (100 µg/mL) was added to the apical compartment of each insert, and the monolayers were incubated for 1 h at 37°C. Monolayer permeability to FITC-dextran was then determined by measuring the fluorescence of the basal solution in each well using a microplate fluorometer (Thermo Fisher Scientific, Waltham, MA, USA) at an excitation wavelength of 485 nm and an emission wavelength of 535 nm. Permeability data were expressed as flux of FITC-Dextran (µg·cm− 2·h− 1). Microscopy images of the Caco-2 monolayer Caco-2 cells were seeded into 6-well plates at a density of 5 × 10⁵ cells/well and cultured until confluent to form a continuous cell monolayer. Subsequently, the cells were treated according to the grouping and treatment conditions described previously. At the end of the experiment, the Caco-2 cell monolayer was observed under a light microscope (Carl Zeiss AG, Oberkochen, Germany), and representative images were captured for documentation. mtDNA extraction and quantification Caco-2 cells were seeded into 6-well plates at a density of 3 × 10⁵ cells per well and cultured for 24 h before treatment as described earlier. To quantify extracellular mtDNA, cell-free supernatant was collected by centrifuging the culture medium at 12,000 × g for 10 min. mtDNA was then purified using the ZR Plasmid MiniPrep Kit according to the manufacturer’s protocol. Quantitative polymerase chain reaction (qPCR) was performed using the SYBR Green dye-based method on a Bio-Rad CFX Connect Real-Time System (Bio-Rad, Hercules, CA, USA). The thermal cycling conditions were: 95 °C for 1 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min, with a final melt curve analysis from 60 °C to 95 °C. Primers specific for human mtDNA used were gene ND1 [15], The cycle threshold (Ct) values were calculated and normalized to the level of a housekeeping gene β-actin. Table 1 displayed the primer sequences. Relative mtDNA levels were calculated using the 2−△△Ct method. Table 1Primer sequencesTargetPrimer sequences (F: Forward primer. R: Reverse primer)β-actin(F) \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$5^\prime$$\end{document}-CACCATTGGCAATGAGCGGTT-\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$3^\prime$$\end{document}(R) \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$5^\prime$$\end{document}-AGGTCTTTGCGGATGTCCACGT-\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$3^\prime$$\end{document}ND1(F) \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$5^\prime$$\end{document}-CACCCAAGAACAGGGTTTGT-\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$3^\prime$$\end{document}(R) \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$5^\prime$$\end{document}-TGGCAATGGGTATGTTGTTA-\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$3^\prime$$\end{document} Table 1Primer sequencesTargetPrimer sequences (F: Forward primer. R: Reverse primer)β-actin(F) \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$5^\prime$$\end{document}-CACCATTGGCAATGAGCGGTT-\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$3^\prime$$\end{document}(R) \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$5^\prime$$\end{document}-AGGTCTTTGCGGATGTCCACGT-\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$3^\prime$$\end{document}ND1(F) \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$5^\prime$$\end{document}-CACCCAAGAACAGGGTTTGT-\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$3^\prime$$\end{document}(R) \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$5^\prime$$\end{document}-TGGCAATGGGTATGTTGTTA-\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$3^\prime$$\end{document} Primer sequences Assessment of mitochondrial membrane potential Mitochondrial membrane potential (ΔΨm) was assessed using the JC-1 fluorescent probe. Briefly, Caco-2 cells were seeded in 6-well plates at 3 × 10⁵ cells/well and cultured for 24 h prior to treatment. After treatment, cells were washed with pre-warmed PBS and incubated with 2 µM JC-1 working solution at 37 °C in the dark for 25 min. Following three washes with staining buffer, coverslips were mounted with antifade medium for observation. Fluorescence images were acquired using a fluorescence microscope (Carl Zeiss AG, Oberkochen, Germany): green fluorescence (JC-1 monomers, low ΔΨm; Ex/Em 490/525 nm) and red fluorescence (JC-1 aggregates, high ΔΨm; Ex/Em 540/590 nm). Preparation of mtDNA The mtDNA used in this study for the treatment of Caco-2 cells was isolated from mouse liver tissue using the mitochondrial DNA isolation kit, according to the manufacturer’s protocol. The concentration of mtDNA was measured by NanoDrop (Thermo Fisher Scientific, Waltham, MA, USA). ELISA Caco-2 cells were seeded in six-well plates at a density of 3 × 105 cells per well and cultured for 24 h before treatment as described earlier. The culture medium was collected and centrifuged at 12,000 × g for 10 min to remove cells and debris. The cell-free supernatant was then used to measure pro-inflammatory cytokines IL-6 and IL-1β using ELISA kits according to the manufacturer’s protocols. A standard curve was generated by serial dilutions of recombinant cytokines, and the concentrations of target cytokines were calculated by linear regression analysis of the standard curve. Statistical analysis Experiments were triplicated with consistent results and representative experiments are shown. The experimental data were processed by GraphPad Prism software version 9.5 (GraphPad Software, Inc., San Diego, CA). One-way analysis of variance was used for inter-group statistics, and Tukey’s multiple comparisons test was applied for multiple group comparisons. P < 0.05 indicated that the data was statistically significant. Results Dose-response of TXA on Caco-2 cell viability The effect of TXA on Caco-2 cell viability was evaluated. Cells were treated with increasing concentrations of TXA (0, 6.3, 15, 24, and 50 µg/mL) for 24 h, and viability was assessed using the CCK-8 assay. As shown in Fig. 2, cell viability (expressed as a percentage of the 0 µg/mL TXA control) was not significantly altered at any tested concentration (P > 0.05). These results indicate that TXA exhibits no cytotoxicity toward Caco-2 cells within the concentration range studied. Fig. 2Dose-effect of TXA on Caco-2 cells viability. The cytotoxic effects of TXA on the Caco-2 cells’ viability were assessed at increasing concentrations of TXA (0, 6.3, 15, 24, and 50 µg/mL) for 24 h by CCK8 assay. The values represent mean ± SD (n = 3), ns: P > 0.05 Dose-effect of TXA on Caco-2 cells viability. The cytotoxic effects of TXA on the Caco-2 cells’ viability were assessed at increasing concentrations of TXA (0, 6.3, 15, 24, and 50 µg/mL) for 24 h by CCK8 assay. The values represent mean ± SD (n = 3), ns: P > 0.05 TXA alleviates intestinal barrier damage induced by OGD/R injury TEER was used to determine the integrity of the membrane monolayer. As shown in Fig. 3a, TEER values were measured at 0, 12, 18, 24, and 30 h after the beginning of the experiment. OGD/R significantly reduced the TEER value of Caco-2 cell monolayers compared with the control group. TXA significantly ameliorated the OGD/R-induced decline in TEER value, and this effect became stronger with the increase of TXA concentration, suggesting that TXA protected intestinal epithelial integrity. The differences were statistically significant. Fig. 3TXA at 6.3 and 24 µg/mL alleviates intestinal barrier damage induced by OGD/R injury. a TEER values were measured at 0, 12, 18, 24, and 30 h after the beginning of the experiment. b The permeability of Caco-2 cells to large solutes was measured in each group using a FITC-dextran permeability assay. The data in the figure represent mean ± SD (n = 3). ***P < 0.0001 compared with the control group; #P < 0.05, ##P < 0.01, ###P < 0.0001 compared with the OGD/R group TXA at 6.3 and 24 µg/mL alleviates intestinal barrier damage induced by OGD/R injury. a TEER values were measured at 0, 12, 18, 24, and 30 h after the beginning of the experiment. b The permeability of Caco-2 cells to large solutes was measured in each group using a FITC-dextran permeability assay. The data in the figure represent mean ± SD (n = 3). ***P < 0.0001 compared with the control group; #P < 0.05, ##P < 0.01, ###P < 0.0001 compared with the OGD/R group We also detected large solute permeability of Caco-2 cells using FITC-dextran permeability assay. The result (Fig. 3b) showed that the FITC-dextran concentrations in the basal compartment were significantly higher after OGD/R compared with the control group. Both TXA concentrations significantly attenuated the OGD/R-induced leakage of FITC-dextran compared with the OGD/R group, suggesting that TXA reduced intestinal epithelial permeability to large solutes. Microscopy images of the Caco-2 monolayer As shown in Fig. 4, in the control and TXA groups, Caco-2 cells grew adherently and interconnected with each other, exhibiting a predominantly polygonal morphology with plump cell bodies. Distinct nuclei were visible in some cells, and the cells were in good overall condition, forming a continuous cell monolayer (Fig. 4a and b). In the OGD/R group, Caco-2 cells appeared rounded and swollen, with numerous translucent vacuoles observed in the field of view, and no clear boundaries existed between cells (Fig. 4c). In the OGD/R + TXA (L) group, some cells showed a shrunken rounded morphology, and intercellular connections were relatively loose (Fig. 4d). In the OGD/R + TXA (H) group, most cells maintained their morphology, with relatively loose intercellular connections (Fig. 4e). However, compared with the OGD/R group, the cell states in both the OGD/R + TXA (L) and OGD/R + TXA (H) groups were significantly improved. Fig. 4Bright-field micrographs of Caco-2 cells in different groups. (a) Control group; (b) TXA group; (c) OGD/R group; (d) OGD/R + TXA (L) group; (e) OGD/R + TXA (H) group. Scale bar = 200 μm Bright-field micrographs of Caco-2 cells in different groups. (a) Control group; (b) TXA group; (c) OGD/R group; (d) OGD/R + TXA (L) group; (e) OGD/R + TXA (H) group. Scale bar = 200 μm TXA suppresses the release of mtDNA in Caco-2 cells Caco-2 cells were treated with OGD/R and TXA, and the release of endogenous mtDNA into the medium was determined. As shown in Fig. 5a, OGD/R significantly increased the release level of endogenous mtDNA compared to the control group, while TXA treatment dose-dependently inhibited this release. We also found that treatment of Caco-2 cells with exogenous murine mtDNA (1 µg/mL, 24 h) stimulated endogenous mtDNA release. This effect was also suppressed by TXA (6.3 and 24 µg/mL) (Fig. 5b). Fig. 5TXA at 6.3 and 24 µg/mL suppresses the release of mtDNA in Caco-2 cells. a Caco-2 cells were treated with OGD/R and TXA, and the release of endogenous mtDNA in the supernatant was determined by qPCR using specific primers for human mtDNA. b Caco-2 cells were treated with 1 µg/mL mouse mtDNA and TXA, and released mtDNA was determined. Mean mtDNA release levels, normalized to the untreated control and presented with standard deviations, are shown (n = 3). ***P < 0.0001 compared with the control group; ###P < 0.0001 compared with the OGD/R group (a) or mtDNA group (b) TXA at 6.3 and 24 µg/mL suppresses the release of mtDNA in Caco-2 cells. a Caco-2 cells were treated with OGD/R and TXA, and the release of endogenous mtDNA in the supernatant was determined by qPCR using specific primers for human mtDNA. b Caco-2 cells were treated with 1 µg/mL mouse mtDNA and TXA, and released mtDNA was determined. Mean mtDNA release levels, normalized to the untreated control and presented with standard deviations, are shown (n = 3). ***P < 0.0001 compared with the control group; ###P < 0.0001 compared with the OGD/R group (a) or mtDNA group (b) TXA enhances mitochondrial membrane potential As shown in Fig. 6, there was no significant difference in mitochondrial membrane potential between the Control group and the TXA group. OGD/R injury reduced mitochondrial membrane potential, while TXA reversed this decrease. Fig. 6TXA at 6.3 and 24 µg/mL reverses the decrease in mitochondrial membrane potential induced by OGD/R injury. (a) Representative images of JC-1 fluorescence (aggregates: red; monomers: green) in each group. (b) Quantitative analysis of the red/green fluorescence intensity ratio of JC-1. Data are shown as mean ± SD (n = 3). ns: P > 0.05, ***P < 0.0001 compared with the control group; ###P < 0.0001 compared with the OGD/R group TXA at 6.3 and 24 µg/mL reverses the decrease in mitochondrial membrane potential induced by OGD/R injury. (a) Representative images of JC-1 fluorescence (aggregates: red; monomers: green) in each group. (b) Quantitative analysis of the red/green fluorescence intensity ratio of JC-1. Data are shown as mean ± SD (n = 3). ns: P > 0.05, ***P < 0.0001 compared with the control group; ###P < 0.0001 compared with the OGD/R group TXA protects against OGD/R-induced inflammation We assessed the levels of IL-6 and IL-1β in the culture supernatants of Caco-2 cells by ELISA. The results showed that OGD/R significantly increased IL-6 and IL-1β production, and this effect was dose-dependently reversed by TXA (6.3 and 24 µg/mL) (Fig. 7). Fig. 7TXA at 6.3 and 24 µg/mL attenuates OGD/R-induced inflammation in Caco-2 cells. Data are shown as mean ± SD (n = 3). *P < 0.05, ***P < 0.0001, ns: P > 0.05 compared with the control group; ###P < 0.0001 compared with the OGD/R group TXA at 6.3 and 24 µg/mL attenuates OGD/R-induced inflammation in Caco-2 cells. Data are shown as mean ± SD (n = 3). *P < 0.05, ***P < 0.0001, ns: P > 0.05 compared with the control group; ###P < 0.0001 compared with the OGD/R group Discussion I/R injury remains a challenging clinical problem, particularly in the gastrointestinal tract. The pathogenesis of intestinal I/R is complex and includes the following critical events: (a) Hypoxia induces extensive death of intestinal epithelial cells and disrupts the epithelial barrier [16]; (b) Mitochondrial oxidative stress leads to mitochondrial dysfunction, enhances ROS production and aggravates mtDNA damage [17]; (c) Calcium overload, in conjunction with ROS, triggers the opening of mitochondrial permeability transition pores, promoting the release of DAMPs (such as mtDNA), organelle swelling, and rupture [18]; (d) The release of DAMPs into the cytoplasm or extracellular induces the activation of proinflammatory mediators and proapoptotic factors [19]; (e) Increased intestinal permeability sustains a pro-inflammatory environment, allowing bacterial translocation and systemic dissemination of cytokines/endotoxins [20]. Fig. 8TXA mitigate intestinal I/R injury by enhancing mitochondrial membrane potential, inhibiting mtDNA release, reducing inflammation, and preserving intestinal barrier integrity. TXA, tranexamic acid TXA mitigate intestinal I/R injury by enhancing mitochondrial membrane potential, inhibiting mtDNA release, reducing inflammation, and preserving intestinal barrier integrity. TXA, tranexamic acid TXA is known to significantly suppress fibrinolysis and decrease of blood loss. However, several publications have shown TXA has multiple beneficial effects that transcend antifibrinolysis, such as its anti-inflammatory activity, protection of the endothelial and epithelial monolayers, stimulation of mitochondrial respiration, and so on [21]. Diebel et al. first reported that early administration of TXA protects the gut barrier in intestinal epithelial cells exposed to hypoxia/reoxygenation and trypsin by inhibiting trypsin uptake and activity, as well as the subsequent downstream protease cascade [22–23]. Peng et al. showed that TXA preserves the integrity of intestinal glycocalyx in hemorrhagic rats [10], while Chu et al. demonstrated that TXA mitigates intestinal epithelial barrier injury in a rat model of hemorrhagic trauma [11]. In our study, TEER and FITC-dextran permeability assays were performed to assess the intestinal barrier function [24]. Results showed that TXA could remarkably increase the TEER value and protect against intestinal hyperpermeability in OGD/R-treated Caco-2 cells. Microscopy images of the Caco-2 monolayer also support the results. The selected TXA concentrations (6.3 and 24 µg/mL) align with therapeutic plasma levels achieved after 10–30 mg/kg loading doses in clinical settings [25], supported by prior cellular efficacy studies [23]. The result of cell viability assay showed that both TXA concentrations exhibited no cytotoxicity toward Caco-2 cells. mtDNA is particularly vulnerable to oxidative stress because of its special location and structure [26]. Several studies have indicated that mtDNA plays an important role in intestinal I/R injury. Hu first identified that intestinal I/R injury causes a significantly increased release of mtDNA originated mainly from IECs, thus leading to local and remote inflammation through inducing the TLR9/MyD88 signal in immune cells [6]. Zhang further proved that mtDNA induces intestinal necroptosis, promoting intestinal I/R injury, and STING signaling is involved in this process [7]. Moreover, clinical studies also have found that the level of circulating mtDNA after gastrointestinal surgery is related to inflammatory response and intestinal barrier damage, which can be used as a marker for early diagnosis of postoperative course [27–28]. Therefore, suppression of mtDNA release could be a potent therapy of the intestinal I/R injury. Rappold et al. showed that TXA significantly decreased the release of mtDNA into the bloodstream in a severe burn mouse model [29], as well as in vitro in cultures of endothelial cells and neutrophils [15]. Our data demonstrated that TXA enhances mitochondrial membrane potential and suppresses the release of mtDNA from OGD/R-treated Caco-2 cells. Moreover, we found that exogenous mtDNA stimulates the release of endogenous mtDNA from Caco-2 cells, and TXA can inhibit this release. This phenomenon is different from Rappold’s finding in endothelial cells, where exogenous mtDNA did not significantly enhance endogenous mtDNA release, and this discrepancy might be attributed to the different durations of exogenous mtDNA exposure to the two cell types. The inhibition of mtDNA release by TXA is attributed to its ability to stabilize the mitochondrial membrane. Additionally, accumulating evidence has demonstrated that TXA can stimulate mitochondrial respiratory activity and biogenesis [15, 30]. These combined actions enhance mitochondrial structural and functional integrity, thereby reducing mtDNA leakage into the cytoplasm. In this study, IL-6 and IL-1β were selected as key inflammatory markers. These cytokines are widely recognized as core early-response pro-inflammatory factors in intestinal I/R injury [1–3]. They can be rapidly induced and play critical roles in amplifying the inflammatory cascade, disrupting the intestinal mucosal barrier, and even triggering remote organ damage, making them ideal indicators for assessing the severity of intestinal inflammatory injury. The production of IL-6 and IL-1β is strongly induced by mitochondrial damage and subsequent mtDNA release [2]—a pathway that aligns with the core mechanistic axis through which TXA is hypothesized to act. Moreover, measuring IL-6 and IL-1β levels represents a standard and widely adopted methodology in preclinical models of intestinal I/R [31]. Our findings demonstrated that TXA significantly reduces the levels of IL-6 and IL-1β in OGD/R‑treated Caco‑2 cells. We have created a new mechanism schematic (Fig. 8) summarizing the key findings of our study: under OGD/R stress, TXA maintains mitochondrial membrane potential, reduces mitochondrial DNA release, and thereby inhibits subsequent inflammatory activation. This cascade underlies TXA’s protective role in preserving the intestinal epithelial barrier, as supported by our experimental data. While our in vitro approach enabled a focused assessment of TXA’s effects without the confounding influence of systemic inflammation present in in vivo models, several key limitations must be acknowledged. The inherent translational gap of cell-based studies means our findings cannot fully replicate the physiological complexity of multi-organ crosstalk, vascular dynamics, or the host immune microenvironment. Mechanistically, the specific tight junction proteins or signaling pathways through which TXA stabilizes the intestinal barrier remain undefined. Furthermore, we have not explored whether TXA modulates critical inflammatory pathways such as TLR9, cGAS-STING, or NLRP3 inflammasome, which are implicated in mitochondrial DNA release and barrier dysfunction. To address these gaps, a structured research plan will be pursued. Our in vitro findings will first be validated in a murine model of intestinal ischemia-reperfusion to evaluate TXA’s efficacy in a physiologically integrated context. Additionally, we will systematically investigate TXA’s potential regulation of the TLR9, cGAS-STING, and NLRP3 inflammasome pathways using combined in vitro and in vivo experimental approaches. This work aims to identify the precise molecular targets of TXA among tight junction components, thereby clarifying its barrier-protective mechanism. Conclusion In conclusion, the current research has demonstrated that TXA can mitigate intestinal I/R injury by enhancing mitochondrial membrane potential, inhibiting mtDNA release, reducing inflammation, and preserving intestinal barrier integrity. Nevertheless, to realize its therapeutic potential, a deeper mechanistic understanding of the effects of TXA in intestinal I/R injury is warranted. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1